EGFR and pancreatic neoplasm: Our study identified that CPX was capable to decrease EGFR at Y1068 and pAKT (S473) levels in pancreatic cancer cells, which, consecutively, inhibit pancreatic cell growth, by the end of the in vivo treatment.